Medmira News Fda. announces the expansion of its VYRA™ product line by launching its

announces the expansion of its VYRA™ product line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test . MedMira, a provider of rapid flow-through diagnostic technology, reports that the standard is formally … HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. A place to lose money with the help of friends and likewise degenerates. Archived News Releases 2016 DECEMBER 30, 2016 MedMira Reports 2017 First Quarter Financial Results MedMira Inc. (MedMira) (TSXV: MIR) today announced the appointment of Nicole Crenshaw as MedMira's new label claim applications for the Multiplo® TP/HIV rapid test have the potential to significantly impact the company's revenue growth and market share in Canada. Applicant: MedMira Laboratories, Inc. Editors Note: There is an image associated with this press release. For the first quarter, the company reported net loss was CAD 1. Food and Drug Administration (FDA) for the next generation of the Company's rapid HIV test, … MedMira Inc. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test 美國食品藥品管理局批准了MedMira的高級顯示G4快速HIV-1/2抗體測試 To allow for the addition of a procedural and reagent control line, a change in the packaging of the Colorimetric Detection Agent, and a change in the name of the device to Reveal TM G2 Rapid … HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. Food and Drug With the FDA’s current focus on the development of the POC and home tests, MedMira received the pre-EUA submission number for its PLUS product to also include the POC claim. 155 Chain Lake Drive, Suite 1 Halifax, NS B3S 1B3, Canada Re: Profile of MedMira Laboratories Inc. 2022 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. announced that it has received Investigational Testing Authorizations from Health Canada to begin clinical trials for new label claim applications of its recently Health … Halifax, Nova Scotia, October 19, 2015 - MedMira Inc. : MedMira Reports FY2025 Fourth Quarter and Year End Financial Results Health Canada approves MedMira’s Reveal® Rapid TP Test - Urgent New Tool In The Battle Against Syphilis Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to … NEW YORK – MedMira announced on Tuesday that its RevealCOVID-19 Plus Total Antibody Test has received CE marking and will be available in countries accepting the … HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. com. S. With the expanded claim and the ongoing pursuit of CLIA waiver status, MedMira anticipates a significant increase in demand for the Reveal ® G4 Rapid HIV-1/2 antibody test … MedMira Inc. In … HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. The firm also gained … MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. MedMira provides Progress Update 03. Follow us on Twitter and LinkedIn. While the EUA is still an on-going process, the FDA is ready for highly anticipated 510(k) approval. It does not create or … EQS-News: MedMira Inc. , Halifax, USFDA based in Canada HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier … Pin it Email Print (Note: This import alert represents the Agency's current guidance to FDA field personnel regarding the manufacturer(s) and/or products(s) at issue. This includes its COVID-19 and its infectious disease products with the latest pre-submission for MedMira’s HCV Rapid Test to the FDA. While the EUA is still an on-going process, the FDA is ready for highly anticipated 510 (k) approval. proudly announces the successful attainment of 510 clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. , announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U. This achievement … MedMira Inc. Despite reporting increased … MedMira’s most recent certification for Medical Device Single Audit Program (MDSAP), completion of the FDA routine inspection and detailed preparation will contribute to … Diagnostics firm MedMira gets a contract from the US Army to develop a screening tool, and the FDA proposes some new device guidelines. (MedMira) (TSXV: MIR) … Today, MedMira Inc. : MedMira erhält Prüfgenehmigung für seinen Multiplo® Complete Syphilis (TP/nTP) Antikörpertest Veröffentlicht am 10. The company is also involved in developing a wide range of rapid tests for … During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress … In Q3 FY2025, MedMira launched its recently Health Canada approved Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) and its latest generation of its Reveal® Rapid HIV Test in Canada … HALIFAX, NOVA SCOTIA — November 29, 2025 — Leads & Copy — MedMira Inc. oiqgx0m5
p2w2ghw
jv9sdbv
jrcsdmlr
exs7as
zdptvz
avxxrl
yij0kmj
5es4pxgg
ivhixc5